Irene Lobon

Irene Lobon

Auto-generated profile, based on publicly available information

Irene Lobon

Cancer Dynamics Laboratory, The Francis Crick Institute, London, United Kingdom

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LSLavinia Spain
Lavinia Spain
ACAlexander Coulton
Alexander Coulton
ILIrene Lobon
Irene Lobon
ARAndrew Rowan
Andrew Rowan
DSDesiree Schnidrig
Desiree Schnidrig
STSamra Turajlic
Samra Turajlic
Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient metastatic melanoma dataset assembled to date as part of the Posthumous Evaluation of Advanced Cancer Environment (PEACE) research autopsy program, including 222 exome sequencing, 493 panel-sequenced, 161 RNA sequencing, and 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed frequent whole-genome doubling and widespread loss of heterozygosity, often involving antigen-presentation machinery. We found KIT extrachromosomal DNA may have contributed to the lack of response to KIT inhibitors of a KIT-driven melanoma. At the lesion-level, MYC amplifications were enriched in ICI nonresponders. Single-cell sequencing revealed polyclonal seeding of metastases originating from clones with different ploidy in one patient. Finally, we observed that brain metastases that diverged early in molecular evolution emerge late in disease. Overall, our study illustrates the diverse evolutionary landscape of advanced melanoma. Significance: Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research autopsy and dense sampling of metastases combined with extensive multiomic profiling, our study elucidates the many mechanisms that melanomas use to evade treatment and the immune system, whether through mutations, widespread copy-number alterations, or extrachromosomal DNA. See related commentary by Shain, p. 1294. This article is highlighted in the In This Issue feature, p. 1275

27 July 2023 in Nature Ecology & Evolution
Verified
Journal Article
Open access
PDF file
HPHarvinder Pawar
Harvinder Pawar
ARAigerim Rymbekova
Aigerim Rymbekova
SCSebastian Cuadros-Espinoza
Sebastian Cuadros-Espinoza
XHXin Huang
Xin Huang
MMMarc de Manuel
Marc de Manuel
MKMARTIN KUHLWILM
MARTIN KUHLWILM
Archaic admixture has had a substantial impact on human evolution with multiple events across different clades, including from extinct hominins such as Neanderthals and Denisovans into modern humans. In great apes, archaic admixture has been identified in chimpanzees and bonobos but the possibility of such events has not been explored in other species. Here, we address this question using high-coverage whole-genome sequences from all four extant gorilla subspecies, including six newly sequenced eastern gorillas from previously unsampled geographic regions. Using approximate Bayesian computation with neural networks to model the demographic history of gorillas, we find a signature of admixture from an archaic ‘ghost’ lineage into the common ancestor of eastern gorillas but not western gorillas. We infer that up to 3% of the genome of these individuals is introgressed from an archaic lineage that diverged more than 3 million years ago from the common ancestor of all extant gorillas. This introgression event took place before the split of mountain and eastern lowland gorillas, probably more than 40 thousand years ago and may have influenced perception of bitter taste in eastern gorillas. When comparing the introgression landscapes of gorillas, humans and bonobos, we find a consistent depletion of introgressed fragments on the X chromosome across these species. However, depletion in protein-coding content is not detectable in eastern gorillas, possibly as a consequence of stronger genetic drift in this species.

26 April 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ARAljosja Rogiers
Aljosja Rogiers
ILIrene Lobon
Irene Lobon
LSLavinia Spain
Lavinia Spain
STSamra Turajlic
Samra Turajlic
Cancer is an evolutionary process that is characterized by the emergence of multiple genetically distinct populations or clones within the primary tumor. Intratumor heterogeneity provides a substrate for the selection of adaptive clones, such as those that lead to metastasis. Comparative molecular studies of primary tumors and metastases have identified distinct genomic features associated with the development of metastases. In this review, we discuss how these insights could inform clinical decision-making and uncover rational antimetastasis treatment strategies.

9 January 2025 in Cancer Discovery
Verified
Journal Article
Open access
ÁFÁngel Fernández-Sanromán
Ángel Fernández-Sanromán
AFAnnika Fendler
Annika Fendler
BTBenjy J.Y. Tan
Benjy J.Y. Tan
ACAnne-Laure Cattin
Anne-Laure Cattin
CSCharlotte Spencer
Charlotte Spencer
STSamra Turajlic
Samra Turajlic
Although the key aspects of genetic evolution and their clinical implications in clear-cell renal cell carcinoma (ccRCC) are well documented, how genetic features coevolve with the phenotype and tumor microenvironment (TME) remains elusive. Here, through joint genomic–transcriptomic analysis of 243 samples from 79 patients recruited to the TRACERx Renal study, we identify pervasive nongenetic intratumor heterogeneity, with over 40% not attributable to genetic alterations. By integrating tumor transcriptomes and phylogenetic structures, we observe convergent evolution to specific phenotypic traits, including cell proliferation, metabolic reprogramming, and overexpression of putative cGAS–STING repressors amid high aneuploidy. We also uncover a coevolution between the tumor and the T-cell repertoire, as well as a longitudinal shift in the TME from an antitumor to an immunosuppressive state, linked to the acquisition of recurrently late ccRCC drivers 9p loss and SETD2 mutations. Our study reveals clinically relevant and hitherto underappreciated nongenetic evolution patterns in ccRCC. Significance: Using joint genomic–transcriptomic analysis of 243 samples, we reveal recurrent patterns of nongenetic evolution in ccRCC not exclusively governed by genetic factors, including T-cell depletion, tumor T-cell receptor coevolution, potential cGAS–STING repression, and increased cell proliferation. These patterns can aid clinical management and guide novel treatment approaches.

26 December 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
ARAljosja Rogiers
Aljosja Rogiers
FDFlorentia Dimitriou
Florentia Dimitriou
ILIrene Lobon
Irene Lobon
CHCatriona Harvey
Catriona Harvey
IVIsmael A. Vergara
Ismael A. Vergara
GLGeorgina Venetia Long
Georgina Venetia Long

2 January 2026 in Nature Immunology
Verified
Journal Article
Open access
PDF file
KLKok Haw Jonathan Lim
Kok Haw Jonathan Lim
OSOliver Schulz
Oliver Schulz
ILIrene Lobon
Irene Lobon
TCTomas Castro-Dopico
Tomas Castro-Dopico
LZLuis Zapata
Luis Zapata
CSCaetano Reis e Sousa
Caetano Reis e Sousa
Type 1 conventional dendritic cells (cDC1s) acquire and cross-present tumor antigens to prime CD8⁺ T cells. Whether this selects for specific neoantigens is unclear. DNGR-1 (CLEC9A), a cDC1 receptor for F-actin exposed on dead cells, promotes cross-presentation of cell-associated antigens. Here we show that DNGR-1-deficient mice develop chemically induced tumors more rapidly and at higher incidence, and these are more frequently rejected on transplantation into wild-type recipients. Whole-exome sequencing reveals enrichment of predicted neoantigens derived from mutated F-actin-binding proteins. Consistent with this observation, tethering model antigens to F-actin enhances DNGR-1-dependent cross-presentation. These results suggest that DNGR-1-mediated recognition of F-actin exposed by dead cancer cells favors priming of CD8⁺ T cells specific for cytoskeletal neoantigens, which can then drive immune escape of cancer cells lacking or reverting those mutations. Thus, neoantigen cross-presentation by cDC1 can determine the immune visibility of the tumor mutational landscape and sculpt cancer evolution by immunoediting.